Cellink Ab Stock Net Income
| CLLKF Stock | USD 1.98 0.02 1.00% |
As of the 6th of February, Cellink AB shows the Standard Deviation of 3.65, risk adjusted performance of (0.06), and Mean Deviation of 1.45. Cellink AB technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cellink AB standard deviation and maximum drawdown to decide if Cellink AB is priced correctly, providing market reflects its regular price of 1.98 per share. Please also double-check Cellink AB jensen alpha, which is currently at (0.32) to validate the company can sustain itself at a future point.
Cellink AB's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cellink AB's valuation are provided below:Cellink AB does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Cellink |
Cellink AB 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cellink AB's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cellink AB.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Cellink AB on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Cellink AB or generate 0.0% return on investment in Cellink AB over 90 days. Cellink AB is related to or competes with Brii Biosciences, Venus Medtech, CYBERDYNE, Paxman AB, NDT Pharmaceuticals, NervGen Pharma, and Molecular Partners. BICO Group AB operates as a bio convergence company in North America, Europe, Asia, and internationally More
Cellink AB Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cellink AB's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cellink AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 28.09 | |||
| Value At Risk | (8.14) |
Cellink AB Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellink AB's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cellink AB's standard deviation. In reality, there are many statistical measures that can use Cellink AB historical prices to predict the future Cellink AB's volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | 0.9594 |
Cellink AB February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 0.9694 | |||
| Mean Deviation | 1.45 | |||
| Coefficient Of Variation | (1,131) | |||
| Standard Deviation | 3.65 | |||
| Variance | 13.29 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | 0.9594 | |||
| Maximum Drawdown | 28.09 | |||
| Value At Risk | (8.14) | |||
| Skewness | (0.03) | |||
| Kurtosis | 11.15 |
Cellink AB Backtested Returns
Cellink AB secures Sharpe Ratio (or Efficiency) of -0.0366, which signifies that the company had a -0.0366 % return per unit of risk over the last 3 months. Cellink AB exposes nineteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cellink AB's Mean Deviation of 1.45, risk adjusted performance of (0.06), and Standard Deviation of 3.65 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.35, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cellink AB are expected to decrease at a much lower rate. During the bear market, Cellink AB is likely to outperform the market. At this point, Cellink AB has a negative expected return of -0.12%. Please make sure to confirm Cellink AB's total risk alpha, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Cellink AB performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.65 |
Good predictability
Cellink AB has good predictability. Overlapping area represents the amount of predictability between Cellink AB time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cellink AB price movement. The serial correlation of 0.65 indicates that roughly 65.0% of current Cellink AB price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.65 | |
| Spearman Rank Test | 0.64 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Cellink AB reported net income of (227.6 Million). This is 166.69% lower than that of the Healthcare sector and 195.59% lower than that of the Medical Devices industry. The net income for all United States stocks is 139.86% higher than that of the company.
Cellink Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellink AB's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cellink AB could also be used in its relative valuation, which is a method of valuing Cellink AB by comparing valuation metrics of similar companies.Cellink AB is currently under evaluation in net income category among its peers.
Cellink Fundamentals
| Return On Equity | 0.0068 | |||
| Return On Asset | -0.025 | |||
| Profit Margin | 0.02 % | |||
| Current Valuation | 973.88 M | |||
| Shares Outstanding | 69.07 M | |||
| Shares Owned By Insiders | 38.50 % | |||
| Shares Owned By Institutions | 26.80 % | |||
| Price To Book | 1.23 X | |||
| Price To Sales | 4.61 X | |||
| Revenue | 1.26 B | |||
| Gross Profit | 1.03 B | |||
| EBITDA | 37.7 M | |||
| Net Income | (227.6 M) | |||
| Total Debt | 1.35 B | |||
| Debt To Equity | 0.26 % | |||
| Current Ratio | 2.35 X | |||
| Cash Flow From Operations | (409.2 M) | |||
| Earnings Per Share | 0.06 X | |||
| Number Of Employees | 1.18 K | |||
| Beta | 2.1 | |||
| Market Capitalization | 657.9 M | |||
| Total Asset | 9.75 B | |||
| Net Asset | 9.75 B |
About Cellink AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellink AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellink AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellink AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Cellink Pink Sheet
Cellink AB financial ratios help investors to determine whether Cellink Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cellink with respect to the benefits of owning Cellink AB security.